Home >
Clinicals Trials >
DS8201-A-U207 DESTINY CRC02

DS8201-A-U207 DESTINY CRC02

A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

Ouvert à Saint-Cloud depuis le : 14/12/2021
Public cible : Adult
Phase : Phase II

Description de l'essai

This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).

Url of the trial